An Evidence-Based Examination of Administration of Infliximab 0761-9999-18-355-H01-P&T Member
10 Questions
An Evidence-Based Examination of Administration of Infliximab 0761-9999-18-355-H01-P&T Member

Remicade (Infliximab [IFX]), the first tumor necrosis factor-alpha (TNF-α) antagonist approved by the U.S. Food and Drug Administration (FDA), has become one of the most prescribed biologic agents in the country and a mainstay of the home infusion industry.  Safe administration requires a comprehensive knowledge  the mechanism of action and prescribing information, as well as the ability to manage and prevent infusion reactions.

NHIA Member ID#
Email








Please wait...

Previous session detected

Resume Quiz